The FDA granted breakthrough therapy and regenerative medicine advanced therapy designations for AURN001 for the treatment of corneal edema secondary to corneal endothelial disease, according to a press release from Aurion Biotech. “Breakthrough therapy and regenerative medicine advanced therapy designations are an important win for the millions of people suffering from corneal endothelial disease,” Greg Kunst, CEO of Aurion Biotech, told Healio. “These designations enable Aurion to work more closely with the FDA on our clinical development plans, which, we believe, should